[Form 4] Alnylam Pharmaceuticals, Inc. Insider Trading Activity
Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals (ALNY), reported multiple open-market sales of Company common stock on 08/29/2025 executed under a Rule 10b5-1 trading plan. The filings show six separate sale transactions totaling 3,474 shares, with weighted average sale prices reported in ranges from approximately $445.32 to $452.54 per share. Following these transactions the reporting person鈥檚 beneficial ownership is reported as 25,992 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Tanguler and includes explanatory notes that each reported price is a weighted average of multiple executions within the stated ranges.
Tolga Tanguler, EVP e Chief Commercial Officer di Alnylam Pharmaceuticals (ALNY), ha comunicato diverse vendite sul mercato aperto di azioni ordinarie della Societ脿 effettuate il 29/08/2025 nell'ambito di un piano di negoziazione Rule 10b5-1. Le comunicazioni mostrano sei operazioni di vendita separate per un totale di 3.474 azioni, con prezzi medi ponderati segnalati in fasce comprese approssimativamente tra $445,32 e $452,54 per azione. Dopo tali operazioni, la partecipazione di propriet脿 effettiva della persona segnalante risulta pari a 25.992 azioni. Il Modulo 4 猫 stato firmato da un procuratore e include note esplicative secondo cui ogni prezzo riportato 猫 una media ponderata di pi霉 esecuzioni all'interno delle fasce indicate.
Tolga Tanguler, EVP y Chief Commercial Officer de Alnylam Pharmaceuticals (ALNY), inform贸 m煤ltiples ventas en el mercado abierto de acciones ordinarias de la Compa帽铆a el 29/08/2025 ejecutadas bajo un plan de negociaci贸n Rule 10b5-1. Las presentaciones muestran seis transacciones de venta separadas por un total de 3.474 acciones, con precios medios ponderados reportados en rangos de aproximadamente $445,32 a $452,54 por acci贸n. Tras estas operaciones, la participaci贸n patrimonial beneficiaria de la persona informante se declara en 25.992 acciones. El Formulario 4 fue firmado por un apoderado y contiene notas explicativas que indican que cada precio informado es un promedio ponderado de m煤ltiples ejecuciones dentro de los rangos indicados.
Alnylam Pharmaceuticals(ALNY)鞚� EVP 瓴� 斓滉碃靸侅梾毂呾瀯鞛�(Tolga Tanguler)電� 2025雲� 8鞗� 29鞚� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤茧ゼ 鞐煬 彀 瓿店皽 鞁滌灔鞐愳劀 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 齑� 3,474欤检棎 雼晿電� 6瓯挫潣 臧滊硠 毵る弰 瓯半灅臧� 鞛堨棃瓿�, 欤茧嫻 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 鞎� $445.32鞐愳劀 $452.54 氩旍渼搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 鞚措摛 瓯半灅 頉� 鞁犼碃鞚胳潣 鞁れ唽鞙� 欤检嫕 靾橂姅 25,992欤茧 氤搓碃霅╇媹雼�. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨溂氅�, 氤搓碃霅� 臧� 臧�瓴╈澊 氇呾嫓霅� 氩旍渼 雮� 雼れ垬 觳搓舶鞚� 臧�欷戫弶攴犾澊霛茧姅 靹る獏鞝� 欤检劃鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Tolga Tanguler, EVP et Chief Commercial Officer d'Alnylam Pharmaceuticals (ALNY), a d茅clar茅 plusieurs ventes en march茅 ouvert d'actions ordinaires de la Soci茅t茅 r茅alis茅es le 29/08/2025 dans le cadre d'un plan de n茅gociation Rule 10b5-1. Les d茅clarations indiquent six op茅rations de vente distinctes totalisant 3 474 actions, avec des prix de vente moyens pond茅r茅s rapport茅s dans des fourchettes d'environ 445,32 $ 脿 452,54 $ par action. 脌 la suite de ces op茅rations, la participation b茅n茅ficiaire de la personne d茅clarante est indiqu茅e 脿 25 992 actions. Le formulaire 4 a 茅t茅 sign茅 par un mandataire et comprend des notes explicatives pr茅cisant que chaque prix rapport茅 est une moyenne pond茅r茅e de plusieurs ex茅cutions au sein des fourchettes indiqu茅es.
Tolga Tanguler, EVP und Chief Commercial Officer von Alnylam Pharmaceuticals (ALNY), meldete mehrere Verk盲ufe von Stammaktien des Unternehmens am 29.08.2025, die im Rahmen eines Rule-10b5-1-Handelsplans ausgef眉hrt wurden. Die Unterlagen zeigen sechs separate Verkaufstransaktionen mit insgesamt 3.474 Aktien, wobei die gemeldeten gewichteten Durchschnittspreise in Spannen von etwa $445,32 bis $452,54 je Aktie angegeben sind. Nach diesen Transaktionen wird das wirtschaftliche Eigentum der meldenden Person mit 25.992 Aktien angegeben. Das Formular 4 wurde von einem Bevollm盲chtigten unterzeichnet und enth盲lt erl盲uternde Hinweise, dass jeder gemeldete Preis ein gewichteter Durchschnitt mehrerer Ausf眉hrungen innerhalb der angegebenen Spannen ist.
- None.
- None.
Insights
TL;DR: Executive sold 3,474 ALNY shares under a pre-established 10b5-1 plan; reported ending ownership 25,992 shares.
The Form 4 discloses routine insider sales by the EVP, executed on 08/29/2025 under a Rule 10b5-1(c) plan adopted May 27, 2025. Six sale lots are reported with weighted average price ranges between roughly $445.32 and $452.54. Such scheduled-plan sales limit managerial inference about contemporaneous company-specific news, but they do reduce the executive鈥檚 direct stake to 25,992 shares. The filing is procedural and contains full explanatory notes about weighted-average pricing for multiple executions.
TL;DR: Sales were made under an established 10b5-1 plan, indicating pre-planned disposition rather than ad hoc trading.
The disclosure clearly cites a 10b5-1(c) trading plan adopted May 27, 2025, which provides an affirmative defense to allegations of trading on material nonpublic information when properly structured. The Form 4 documents multiple sale transactions on a single date with explicit weighted-average price ranges and reports the post-transaction beneficial ownership. From a governance standpoint, the filing meets typical transparency standards for insider transactions.
Tolga Tanguler, EVP e Chief Commercial Officer di Alnylam Pharmaceuticals (ALNY), ha comunicato diverse vendite sul mercato aperto di azioni ordinarie della Societ脿 effettuate il 29/08/2025 nell'ambito di un piano di negoziazione Rule 10b5-1. Le comunicazioni mostrano sei operazioni di vendita separate per un totale di 3.474 azioni, con prezzi medi ponderati segnalati in fasce comprese approssimativamente tra $445,32 e $452,54 per azione. Dopo tali operazioni, la partecipazione di propriet脿 effettiva della persona segnalante risulta pari a 25.992 azioni. Il Modulo 4 猫 stato firmato da un procuratore e include note esplicative secondo cui ogni prezzo riportato 猫 una media ponderata di pi霉 esecuzioni all'interno delle fasce indicate.
Tolga Tanguler, EVP y Chief Commercial Officer de Alnylam Pharmaceuticals (ALNY), inform贸 m煤ltiples ventas en el mercado abierto de acciones ordinarias de la Compa帽铆a el 29/08/2025 ejecutadas bajo un plan de negociaci贸n Rule 10b5-1. Las presentaciones muestran seis transacciones de venta separadas por un total de 3.474 acciones, con precios medios ponderados reportados en rangos de aproximadamente $445,32 a $452,54 por acci贸n. Tras estas operaciones, la participaci贸n patrimonial beneficiaria de la persona informante se declara en 25.992 acciones. El Formulario 4 fue firmado por un apoderado y contiene notas explicativas que indican que cada precio informado es un promedio ponderado de m煤ltiples ejecuciones dentro de los rangos indicados.
Alnylam Pharmaceuticals(ALNY)鞚� EVP 瓴� 斓滉碃靸侅梾毂呾瀯鞛�(Tolga Tanguler)電� 2025雲� 8鞗� 29鞚� Rule 10b5-1 瓯半灅 瓿勴殟鞐� 霐半澕 須岇偓 氤错喌欤茧ゼ 鞐煬 彀 瓿店皽 鞁滌灔鞐愳劀 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 齑� 3,474欤检棎 雼晿電� 6瓯挫潣 臧滊硠 毵る弰 瓯半灅臧� 鞛堨棃瓿�, 欤茧嫻 臧�欷戫弶攴� 毵る弰臧�瓴╈潃 鞎� $445.32鞐愳劀 $452.54 氩旍渼搿� 氤搓碃霅橃柎 鞛堨姷雼堧嫟. 鞚措摛 瓯半灅 頉� 鞁犼碃鞚胳潣 鞁れ唽鞙� 欤检嫕 靾橂姅 25,992欤茧 氤搓碃霅╇媹雼�. Form 4電� 雽�毽澑鞚� 靹滊獏頄堨溂氅�, 氤搓碃霅� 臧� 臧�瓴╈澊 氇呾嫓霅� 氩旍渼 雮� 雼れ垬 觳搓舶鞚� 臧�欷戫弶攴犾澊霛茧姅 靹る獏鞝� 欤检劃鞚� 韽暔頃橁碃 鞛堨姷雼堧嫟.
Tolga Tanguler, EVP et Chief Commercial Officer d'Alnylam Pharmaceuticals (ALNY), a d茅clar茅 plusieurs ventes en march茅 ouvert d'actions ordinaires de la Soci茅t茅 r茅alis茅es le 29/08/2025 dans le cadre d'un plan de n茅gociation Rule 10b5-1. Les d茅clarations indiquent six op茅rations de vente distinctes totalisant 3 474 actions, avec des prix de vente moyens pond茅r茅s rapport茅s dans des fourchettes d'environ 445,32 $ 脿 452,54 $ par action. 脌 la suite de ces op茅rations, la participation b茅n茅ficiaire de la personne d茅clarante est indiqu茅e 脿 25 992 actions. Le formulaire 4 a 茅t茅 sign茅 par un mandataire et comprend des notes explicatives pr茅cisant que chaque prix rapport茅 est une moyenne pond茅r茅e de plusieurs ex茅cutions au sein des fourchettes indiqu茅es.
Tolga Tanguler, EVP und Chief Commercial Officer von Alnylam Pharmaceuticals (ALNY), meldete mehrere Verk盲ufe von Stammaktien des Unternehmens am 29.08.2025, die im Rahmen eines Rule-10b5-1-Handelsplans ausgef眉hrt wurden. Die Unterlagen zeigen sechs separate Verkaufstransaktionen mit insgesamt 3.474 Aktien, wobei die gemeldeten gewichteten Durchschnittspreise in Spannen von etwa $445,32 bis $452,54 je Aktie angegeben sind. Nach diesen Transaktionen wird das wirtschaftliche Eigentum der meldenden Person mit 25.992 Aktien angegeben. Das Formular 4 wurde von einem Bevollm盲chtigten unterzeichnet und enth盲lt erl盲uternde Hinweise, dass jeder gemeldete Preis ein gewichteter Durchschnitt mehrerer Ausf眉hrungen innerhalb der angegebenen Spannen ist.
FAQ
What did Tolga Tanguler (ALNY) report on the Form 4?
Were the sales by the ALNY executive part of a pre-established plan?
What price information is reported for the ALNY sales?
When were the transactions executed according to the filing?
Who signed the Form 4 for Tolga Tanguler?
